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The heavy and light chains of immunoglobulins (Ig) consist of two distinct regions: 
variable and constant. Variable regions, which determine the antibody specificity and 
idiotypic determinants, are further divided into three hypervariable regions and four 
relatively invariant, so-called framework, regions (1, 2). The variable regions of both 
heavy chains  (VH)  1 and  light chains  (VL)  have been divided into subgroups based 
upon  similarities  between  amino  acid  sequences  in  their  framework  regions.  For 
human Ig, three major VH subgroups have been characterized on the basis of amino 
acid sequences of the aminoterminal 20 residues within the first framework region (2). 
One set of goat antibodies specific for each human VH subgroup has been prepared 
by selective adsorption and was found to be useful in typing secreted and membrane- 
bound Ig on B cells (3). 
Evidence from studies  (4-8)  using anti-idiotype antibodies has suggested  that  T 
cells and their antigen-specific, soluble factors might possess  Ig-like idiotypic deter- 
minants. VH allotypic determinants have also been demonstrable on rabbit T  cells by 
several groups  (9,  10) and not by others (11-15). Antibodies against  VH framework 
regions  of the  mouse  myeloma  protein  MOPC-315,  which  cross-react  with  other 
mouse Ig regardless of their antibody specificity, class, subclass, subgroup, or allotype 
(16), may inhibit T  cell function (17-19) and cross-react with soluble factors ofT cells 
(20,  21).  The molecular nature of antigen receptors on T  lymphocytes, however, is 
still controversial. Recent studies  (22, 23) using recombinant DNA techniques have 
suggested that antigen-specific helper or killer T cell clones may not use the Ig-joining 
and constant gene segments. 
We  prepared  monoclonal  hybridoma  antibodies  against  VH  fragments  isolated 
from  human  IgM  myeloma proteins  with  the  hope  of using  these  to  analyze  the 
products of normal or abnormal B and T  cells.  This paper describes the preparation 
and characterization of four such monoclonal anti-human VH antibodies. Our studies 
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1 Abbreviations  used in  this paper."  anti-Cn, antibodies to heavy chain isotype; anti-Cz, antibodies to light 
chain type; anti-Id, antibodies to idiotypic determinants; AP, alkaline  phosphatase; BSB, borate saline 
buffer;  cIg, cytoplasmic imrnunoglobulins;  ELISA,  enzyme-linked immunosorbent assay;  FCS,  fetal calf 
serum;  FITC, fluorescein isothiocyanate;  HAT, hypoxanthine-aminopterin-thymidine;  NTCB, 2-nitro-5- 
thiocyanobenzoic acid;  PBL,  peripheral blood lymphocytes;  PBS, phosphate-buffered saline;  PHA, phy- 
tohemagglutinin; RITC, rhodamine isothiocyanate;  SDS-PAGE, sodium dodecyl  su[fate-polyacrylamide 
gel electrophoresis;  sIg, surface immunoglobulins; Vn, variable portions of immunoglobulin heavy chains; 
VL, variable portions of immunoglobulin light chains;  V/~, variable portions of/x heavy chains. 
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show that monoclonal Vn-specific antibodies are more readily prepared using isolated 
VH  fragments  as  immunogens  and  that  these  antibodies are  specific  for  "hidden" 
determinants not exposed on intact Ig molecules. 
Materials  and  Methods 
Mice.  Inbred BALB/c and (BALB/c x  C57BL/6)FI hybrid (CB6) mice were obtained from 
The Jackson Laboratory, Bar Harbor, ME, and used at 2-3 mo of age. 
Isolation of Vtz Fragments  from Human IgM Paraproteins.  IgM paraproteins were isolated from 
the sera of patients with WaldenstrSm's macroglobulinemia or multiple myeloma by repeated 
euglobulin precipitation against distilled water, followed by gel filtration on a  Sepharose 6B 
(Pharmacia Fine Chemicals, Div. of Pharmacia Inc., Piscataway, N  J) column equilibrated with 
borate saline buffer, pH 8.3, ionic strength, 0.1 (BSB). The elution peak containing pentameric 
IgM was pooled, concentrated, and dialyzed against 0.1 M Tris-HC1 buffer, pH 8.6, containing 
2 mM EDTA. Some of the IgM paraproteins with known VH and VL subgroups were kindly 
provided by Dr. J. D. Capra (University of Texas, Dallas, TX). The purity of isolated IgM was 
tested by immunoelectrophoresis and  double diffusion in agar,  using antisera or antibodies 
specific for normal whole serum proteins, IgM, IgG, and IgA. 
V~ fragments were isolated from IgM paraproteins by a modification of methods described 
by Rodwell and Karush (24). The amount of 2-nitro-5-thiocyanobenzoic  acid (NTCB; Eastman 
Kodak Co., Rochester, NY) for cyanylation of the sulfhydryl groups of reduced IgM was used 
at a ratio of NTCB/IgM of 5 mg/I00 mg. This ratio corresponded approximately to a five-fold 
molar excess of NTCB  to protein-associated sulfhydryt groups. NTCB was used in this study 
without purification, although its melting point was 2-3°C lower than the reported value (25). 
The reaction mixture containing the cleavage products was lyophilized, dissolved in 3 ml of 5 
M guanidine-HC1, pH 7.0, containing 2 mM EDTA, and then applied to a calibrated Sephadex 
G-150 column equilibrated with the same denaturant. The fractions containing V/L fragments, 
which  eluted  after  the  light  chain  peak,  were  collected,  dialyzed against  BSB  to  remove 
guanidine, and then purified further by passage through a Sepharose 4B column to which the 
homologous light chains were coupled  (26).  The bound V/~ fragments were eluted from the 
column by 0.05 M glycine-HC1 buffer, pH 2.8, neutralized with BSB, and then dialyzed against 
saline before use for immunization. 
IgG, IgA, and IgD myeloma proteins were also isolated by salt fractionation, DEAE ion- 
exchange  cellulose column  chromatography,  and  Sepharose  6B  gel  filtration, as  described 
elsewhere (27). IgE)k myeloma protein (PS, VHIII, ghlII) was a gift from Dr. K. Ishizaka (Johns 
Hopkins University, Baltimore, MD). Heavy and light chains were isolated by partial reduction 
and  alkylation of purified  myeloma  Ig or  pooled  normal  IgG  followed  by  separation  on 
Sephadex G-200 in 5 M  guanidine-HC1, pH  7.0. Sodium dodecyl sulfate-polyacrylamide gel 
electrophoresis (SDS-PAGE) was performed in slabs of 5-20% acrylamide gradient gels in Tris- 
HCI buffer, as described by Laemmli (28). 
Immunization.  BALB/c and CB6 mice were immunized 6-7 times with 80-100/~g of purified 
V/~ fragments, isolated /z chains, or intact myeloma proteins at  3- or 7-d intervals. In some 
cases, mice were immunized with Vbt fragments at  14-d  intervals for the first four injections, 
rested for 2 mo, and then immunized again at 7-d intervals for the last three injections. The 
first injection was always given with complete Freund's adjuvant (Difco Laboratories, Detroit, 
MI), the second in incomplete Freund's adjuvant, and the remainder in saline. All mice were 
immunized subcutaneously in footpads, inguinal, and axillary regions. Mice were killed 1 d 
after the last immunization, and the cells from the draining popliteal, inguinal, axillary, and 
para-aortic lymph nodes were prepared by gentle teasing and used for fusion. 
Preparation of Monoclonal Anti-VH Antibodies.  Lymph node cells from immunized mice were 
fused  with  an  equal  number  of P3-X63-Ag.8.653  cells, a  non-Ig-producing variant  of the 
hypoxanthine-aminopterin-thymidine (HAT)-sensitive BALB/c  myeloma cell  line  P3-X63- 
Ag.8, by using polyethylene glycol 4000 (Fisher Scientific Company, Atlanta, GA), as described 
previously  (29,  30).  The  cells  were  plated  into  24-well  plates  (Costar,  Data  Packaging, 
Cambridge, MA) at a cell concentration of 2 ×  105 cells/ml in the HAT medium. 2-3 wk after 
fusion, culture supernatants  from  the wells were screened  for antibody activity against the 1012  ANTI-HUMAN VIJ  ANTIBODIES 
various immunogens  by an enzyme-linked  immunosorbent  assay (ELISA) (31). Affinity-purified 
goat  anti-mouse •  and ~.  antibodies labeled with  alkaline phosphatase  (AP)  were  used  as 
second-step reagents (31). After detecting hybrid-containing  wells with antibody activities, the 
antibody specificities  were tested further by ELISA against a panel of 8-12 different purified 
antigens, including V/~ fragments, various intact Ig, isolated heavy or light chains, and F(ab')2 
fragments of normal IgG.  Hybridomas that  secreted  antibodies reacting with  common or 
homologous VH determinants in this initial screening were  then chosen for further study and 
recloned by limiting dilution on syngeneic normal mouse peritoneal exudate feeder cells. The 
Ig isotypes  of the hybridoma antibodies were  also determined at this stage using AP-labeled 
goat antibodies specific for mouse #, y~, y2a, 7"25, Y3, c~, K, and 3, chain determinants, as described 
elsewhere  (32). 
10-30 million cells from positive reclones were injected intraperitoneally  into syngeneic mice 
previously primed with pristane (Aldrich, Milwaukee WI). Ascites were harvested, and mono- 
clonal anti-Vn antibodies were purified from the ascites  fluid by absorption to Sepharose 4B 
coupled with the appropriate antigens. Bound antibodies were eluted from the column by 0.05 
M glycine-HCl buffer, pH 2.8. In some experiments, antibodies precipitated from hybridoma 
ascites by 60% saturation of ammonium sulfate were used as the anti-Vn antibody preparation 
after dialysis against BSB. 
Radioimmunoassay.  The specificity of monoclonal anti-VH antibodies was examined by using 
a  solid-phase, direct  binding radioimmunoassay. 96-well  polyvinyl plastic plates  (Dynatech 
Laboratories,  Inc.,  Alexandria, VA)  were  coated  with  anti-Vn antibodies  (10  /Lg/ml)  by 
overnight incubation at  room  temperature.  After washing and saturating free  sites  on  the 
plastic plates with  1% bovine serum albumin (Sigma Chemical Co.,  St.  Louis, MO)  in BSB, 
various concentrations of purified antigens, including intact Ig and isolated heavy or light 
chains, were added to the antibody-coated wells in triplicate and incubated for 4 h at 37°C. 
After washing out unbound antigens, 125I-labeled monoelonal hybridoma antibodies specific 
for human/~, y, K, or ~. determinants (~ 105 cpm/100 btl) were added to each well and incubated 
for 4 h at 37°C. Unbound radioactivity was washed out with BSB, and the wells were counted 
in a gamma counter. All monoclonal hybridoma antibodies used for ~25I-labeling were purified 
by affinity chromatography. 
Cell Preparation.  Peripheral blood lymphocytes (PBL)  were isolated from normal adults by 
Ficoll-Hypaque density gradient centrifugation. Bone marrow specimens were obtained with 
informed consent  from  normal  volunteers or  patients with  monoclonal gammopathies  by 
aspiration and with parental consent from fetuses  aborted for reasons of maternal health by 
suction curettage. Mononuclear cells were isolated from bone marrow samples by previously 
described methods (33). Gestational age was estimated by measuring long bone length (34). 
Normal tonsillar and splenic tissues were dispersed into a single cell suspension by gentle teasing 
in phosphate-buffered saline (PBS)  containing 5% fetal calf serum (FCS; Flow Laboratories 
Inc., Rockville, MD.). The use of these materials for research purposes was approved by the 
University of Alabama in Birmingham committee on human experimentation. After washing 
with PBS containing 5% FCS, the cells were  resuspended in RPMI  1640 supplemented with 
20% FCS and incubated in plastic plates for 1 h at 37°C to remove adherent cells and cytophilic 
IgG. T  cells were enriched from PBL by rosette formation with 2-aminoethyl-isothiouronium 
bromide (AET; Sigma Chemical Co.)-treated sheep erythrocytes and density gradient separa- 
tion  (35). In some experiments, PBL  or enriched T  cells  were  cultured in the  presence of 
phytohemagglutinin M  (PHA, 5/tl/ml) at a cell concentration of 5 ×  10  ~ cells/ml of RPMI 
1640 containing 20% FCS for 2 d at 37°C under 5% CO2. 
Immunofluorescent Analyszs of Cells.  The characteristics of VH + cells were determined by two- 
color immunofluorescence  as previously described (27, 33). For surface staining, 106 viable cells 
were incubated with  10 ~1 of monoclonal anti-Vn antibodies (0.5 mg/ml) for 20 min at 4°C, 
washed, and stained with 10/~1 of rhodamine-isothiocyanate  (RITC)-labeled F(ab')2y fragments 
of rabbit  anti-mouse  Ig  antibodies  (0.4  mg/ml;  P/R  ratio,  2.1).  After  washing  out  free 
conjugates, the cells were counterstained with 10/tl of fluorescein isothiocyanate (FITC)-labeled 
goat  anti-human Ig antibodies  (0.5 mg/ml;  F/P  ratio,  3.5).  FITC-labeled goat  antibodies 
specific for human Ig isotype ~, y, a, ~) were also used for counterstaining. After washing, the 
doubly stained cells were cytocentrifuged onto glass slides, fixed in 95% ethanol-5% acetic acid KUBAGAWA, MAYUMI, KEARNEY,  AND  COOPER  1013 
at -20°C, rehydrated in PBS, and then mounted in Elvanol.  Smears of unstained cells were 
similarly prepared by cytocentrifugation, fixed, and stained with one-fifth the concentration of 
the same reagents. Both affinity-purified antibodies for labeling with RITC (anti-mouse  Ig) or 
FITC (anti-human Ig or anti-isotype)  were extensively absorbed with normal pooled human Ig 
and human IgM myeloma proteins or with normal pooled mouse Ig and mouse IgM myeloma 
proteins, respectively. Pre-B cells, B lymphocytes, and plasma cells expressing Vri determinants 
were identified as previously described  (27, 33). 
Results 
Purification of V# Fragments by Affinity Chromatography.  V# fragments were isolated 
from human IgM myeloma proteins by the following steps:  (a)  reduction of interdi- 
sulfide bonds of IgM molecules with dithiothreitol, (b) cyanylation of their sulfhydryl 
groups  with  NTCB,  and  (c)  cleavage of IgM  molecules at  the  amino  side  of the 
cyanylated residues by alkaline pH, as described by Rodwell and Karush  (24). The 
isolation profile of such a  reaction mixture,  as determined by Sephadex G-150 gel 
filtration in 5 M  guanidine-HCl, was essentially the same as their reported profile on 
Sephacryl S-200  gel  filtration. The V/.t peak,  however, contained a  few additional 
protein  fragments  that  migrated  between  the  light  chain  and  V#  bands  on  SDS- 
PAGE  (Fig.  1).  These  protein  fragments  (or  side  products)  did  not  decrease  in 
quantity, even after reduction of the molar ratio of NTCB/IgM from a 25- to a 5-fold 
excess (data not shown). Subsequent cleavage was done at a five-fold excess. 
When the Vpt fragments containing side products from a  Sephadex G-150 column 
were applied to a  Sepharose 4B column coupled with the homologous light chains, 
only the Vbt fragments bound to the light chain column. The elution of V# fragments 
by acid buffer afforded highly purified V/~ fragments (Fig.  1, lane  1). 
These findings indicate that  V#  fragments  isolated by selective cyanylation and 
cleavage can bind to the homologous light chains under physiological conditions, and 
this provides an efficient method of purifying isolated V# fragments. 
Production of Monoclonal Anti-Vz4 Antibodies.  In  our  initial  attempts  to  prepare 
monoclonal antibodies to common Vrt determinants, we immunized mice with intact 
Ig molecules or isolated heavy chains. The culture supernatants from 6-24% of wells, 
FIG.  1.  SDS-PAGE of isolated  V/t fragments by affinity chromatography using the homologous 
light chain coupled column. V# samples isolated from Sephadex G-150 gel filtration (lane 3) were 
applied onto Sepharose 4B coupled with the homologous light chains. The bound V# fragments 
were eluted from the column by acid buffer (lane  1). Lane 2 is the fraction of  V# samples that failed 
to bind to the column. Lane 4 shows the marker proteins, # heavy chain and g light chain. 1014  ANTI-HUMAN VH ANTIBODIES 
containing  lymph node cells derived hybridomas from mice immunized with  intact 
IgMx  (SA,  VHI, and  VK,  untyped),  IgDX  (010),  or IgE2t  (PS,  VmlI, Vxm),  showed 
antibody activity against the immunizing antigens (Table I). 40-70% of these positive 
wells contained antibody specific for the heavy chain isotype of the immunogen (anti- 
Cn);  i.e., anti-/t,  anti-& or anti-e.  About  10-30%  had antibody specific for the light 
chain  type  of  the  homologous  immunogen  (anti-CL),  i.e.,  anti-x  or  anti-)t.  The 
remaining  positive  wells  produced  antibodies  reactive  only  with  the  homologous 
intact  myeloma proteins,  probably anti-idiotype  (anti-Id).  None of the  monoclonal 
antibodies  prepared  in  this  way were  reactive with  isolated  V#  fragments or with 
multiple  heavy  chain  isotypes.  Similarly,  the  culture  supernatants  of hybridomas 
derived  from mice immunized  with  the/1  chain  (007,  VHnI)  showed  mostly anti-/t 
activities, except for one well that reacted only with the homologous intact myeloma 
protein; no anti-VH antibodies were detected. 
In contrast to the above results, when hybridomas were derived from mice immu- 
nized with  isolated V/t fragments, 6-12% of wells contained  hybridomas producing 
antibodies against the V# immunogen, the parent IgM molecules, or isolated/t chains. 
About 30-50% of these positive wells showed antibody activities to VH determinants, 
30-50%  to/t chains,  0-10%  to light  chains,  and  10-50%  to  idiotypic determinants. 
Two hybrid-containing wells were untyped; one of them, resulting from the fusion of 
V/t  (SA)  immunized  cells,  produced  antibody  reactive with  all  myeloma proteins 
tested as well as bovine serum albumin-coated plates, and the other, formed by fusion 
of V/t  (NF)  immunized cells,  reacted  with  the  homologous  intact  IgM and  one of 
seven unrelated myeloma proteins. The latter antibody brightly stained the cytoplasm 
of all normal bone marrow cells, including myeloid cells, as determined by immuno- 
fluorescence. 
Among  11  anti-VH wells  from the  fusion  of V/t  (NF)-immunized  cells,  6  reacted 
with  several  V/t  fragments,  including  homologous  V/t  fragments,  one  with  the 
homologous V/t fragment only, and the other four with homologous V/t, several intact 
myeloma proteins,  and  F(ab')2 fragments of normal IgG. Three anti-VH wells from 
the fusion of V/t (MH)-immunized cells and eight anti-VH wells from the fusion of V/t 
(SA)-immunized cells showed  a  similar spectrum of specificities within  each group. 
Even  though  V/t  fragments  purified  by  elution  from  an  affinity  column  bearing 
homologous  light  chains  were  used  as  immunogens,  some  of the  fused  cells  from 
TABLE  I 
Specificity of Monoclonal Anti-lmmunoglobulin Antibodies 
Number of wells 
Immunogen  positive/total* 
Number of wells with the following specificities:~ 
Anti-CH  Anti-CL  Anti-Id  Anti-VH  Untyped 
IgMK (SA)  42/192  23  l 3  6  0  0 
IgDX (010)  34/144  23  4  7  0  0 
IgEN (PS)  26/432  10  3  13  0  0 
/~ (007)  30/168  29  0  1  0  0 
V/t (MH)  10/150  5  1  1  3  0 
V/I (SA)  16/264  5  0  2  8  1 
V# (NF)  27/220  8  3  4  11  1 
* Positive wells contained a single heavy chain and light chain isotype and antibody activity against the 
immunogen. 
:~ Specificity  was determined by ELISA using plastic plates coated with 8-12 different antigens. KUBAGAWA, MAYUMI, KEARNEY, AND COOPER  1015 
immunized mice produced antibodies against light chains. 
These findings indicate that, at least in our hands, hybridomas secreting anti-VH 
antibodies can be efficiently produced by the fusion of cells from mice immunized 
with isolated V/~ fragments, but not with intact Ig molecules or isolated heavy chains. 
Fine Specificity of Monoclonal Anti-VH Antibodies.  Four  representative  monoclonal 
anti-VH antibodies were prepared by recloning hybridoma clones in limiting dilution 
and used in this study. MH-44, NF-11, and SA-44 were derived from the fusion of 
cells from mice immunized with V# (MH), V~ (NF), and V/~ (SA), respectively (see 
Table I).  GB-24 was  derived from the  fusion of cells immunized by V/~  (GB)  (not 
shown in Table I). The MH-44 and GB-24 monoclonal antibodies were/u¢ in isotype, 
and NF-11 and SA-44 were ylK antibodies. 
To determine the VH specificity of these monoclonal antibodies, we conducted the 
following radioimmunoassay.  Various concentrations of homologous intact  IgM or 
isolated ~  or light chains were added  to wells precoated with  monoclonal anti-Vn 
antibodies,  x25I-labeled  monoclonal anti-human #  or 125I-labeled  mixtures of mono- 
clonal antibodies to human K and ~ chains were used to measure the bound IgM or 
/~ chains or the bound light chains, respectively. As shown in Fig. 2, all four monoclonal 
anti-VH antibodies reacted well with homologous/~ chains, but minimally with intact 
homologous IgM  molecules  and  light  chain  preparations.  MH-44  appeared  to  be 
reactive  with  the  homologous  IgMr  (MH)  at  the  highest  concentration  in  this 
experiment.  This  preparation  of IgMJ¢  (MH)  had  been  stored  at  4°C  for several 
months and might have undergone a  degree of spontaneous degradation. Indeed, in 
another experiment, freshly thawed IgMK (MH) preparations from storage at -20°C 
showed no reactivity with MH-44 over the same range of concentrations (data not 
shown). The observation that the anti-VH antibodies failed to react significantly with 
the homologous intact IgM and light chains was not because of binding properties of 
the second antibodies used in the above assay system because (a)  monoclonal anti- 
human/L antibodies used for iodination bound to intact IgM molecules as well as to 
the isolated ~ chains, and the same was true for a  mixture of monoclonal anti-K and 
anti-~ antibodies, and (b) the amounts of both 12~I-labeled anti-# and 12SI-labeled anti- 
light  chain  reagents  to be added  were adjusted  to give the same cpm to the wells 
precoated with intact IgM molecules. Furthermore, the wells precoated with mono- 
clonal anti-Vn antibodies (10 #g/ml) exhibited <1% binding of 125I-labeled  homolo- 
gous intact myeloma Ig, whereas the wells coated with monoclonal anti-Id antibodies 
(10 #g/ml) derived from the same fusion showed 60-70% binding. 
Similarly,  all  four  anti-Vn  antibodies  reacted  with  pooled  normal  ~,  chains  at 
different degrees but did not react with the intact IgG molecules or light chains (data 
not shown). 
Table II shows the reactivity of these anti-Va antibodies against a panel of human 
myeloma heavy chains as determined by ELISA on antigen-coated plates. This assay 
system was usually used for screening the hybridoma clones secreting anti-Vn anti- 
bodies. Their VH reaction spectra overlapped but were distinctive.  MH-44 reacted 
with one of two Vrti myeloma and one VHn myeloma heavy chains but not with four 
VHnI myeloma heavy chains tested. GB-24 reacted with one of two VHI myeloma and 
four VHm myeloma proteins, but not with a VHn myeloma protein. Both NF- I 1 and 
SA-44 were reactive with one of two Va~ myeloma and two of four VHm myeloma 
heavy chains. D 
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Fro. 2.  Direct binding radioimmunoassay of monoclonal anti-VH antibodies to their homologous 
immunoglobulin  components. The plates were precoated  with the following monoclonal anti-Vn 
antibodies (10 #g/ml). (A) MH-44, (B) GB-24, (C) NF-1  l, and (D) SA-44. Various concentrations 
of their homologous intact IgM (E]), homologous/~ chains (O), or homologous light chains (&) were 
added.  The bound  IgM or #  chains  were measured  by ]2SI-labeled monoclonal  anti-human /~ 
antibodies,  and  the  bound  light  chains  were measured  by  12SI-labeled  mixture  of monoclonal 
antibodies to human I¢ and )t determinants. 
Similar results were obtained by immunofluorescent  staining for the plasma cells 
from  patients  with  monoclonal  gammopathies  (multiple  myeloma,  Waldenstr6m's 
macroglobulinemia, benign monoclonal gammopathy, and light chain disease) (Table 
III).  Among  20  cases  of monoclonal  gammopathies,  excluding  light  chain  disease, 
MH-44  anti-VH antibodies were reactive with 8  cases (2#,  16,  3y, 2a), GB-24 with 5 
cases (1#,  16, 3y), NF-11  with 5 cases (2/x, 2y,  la), and SA-44 with 3 cases (3/~). None 
of the affected cells from individuals with light chain disease were VH +. 
Taken together, these results suggest that (a) these anti-VH antibodies recognize VH 
determinant(s)  only and  not  combinatorial determinants of VH  and  VL portions of 
the  Ig  molecules;  (b)  the  VH  reaction  spectra  for  a  panel  of  myeloma  Ig  show 
overlapping but distinctive patterns for the four antibodies, indicating that each sees 
a  different VH determinant;  and  (e)  these monoclonal antibodies recognize common 
VH  determinant(s),  the distribution of which  does not conform  to the conventional 
VH subgroup assignment. 
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TABLE II 
Reactivity of Monoctonat Anti-Vn Antibodies, as Determined by ELISA, Using 
Myeloma Heavy Chain-coated  Plates 
1017 
Heavy  VH 
Donor  chain 
antigen  subgroup 
Monoclonal anti-VH antibodies 
MH-44  GB-24  NF- 11  SA-44 
GA  la  I  +  +  +  + 
001  al  I  .... 
003  a 1  II  +  -  -  - 
SA  #  III  -  +  +  + 
007  #  III  -  +  +  + 
McK  /z  III  -  +  -  -- 
PS  ~  III  -  +  -  - 
MH  #  ND*  +  +  -  -- 
GB  #  ND  +  +  -  + 
NF  #  ND  -  -  +  + 
DOS  #  ND  -  -  -  + 
01o  6  ND  +  +  -  - 
MG  y  ND  +  +  +  - 
* Not determined. 
Lineages.  To examine whether normal human plasma cells, lymphocytes, and pre-B 
cells  may express  the  determinants recognized by  these  monoclonal anti-VH anti- 
bodies,  indirect  immunofluorescence was  used.  Substantial proportions of normal 
plasma cells from bone marrow, spleen, and tonsils were stained for their cytoplasmic 
Ig (cIg) with the anti-Vn antibodies (Table IV). MH-44, GB-24, and NF-11 stained 
24-34%,  14-24%, and  13% of the total cIg  ÷ plasma cells, respectively. SA-44 showed 
less reactivity with normal plasma cells (~3%). A pool of the four monoclonal anti-VH 
antibodies reacted with ~55% of the total plasma cells, whereas the sum of each VH  + 
frequency was 67%, suggesting overlapping VH reactivities with these antibodies. All 
VH  +  plasma  cells  were  also  stained  with  polyvalent  anti-human  Ig  antibodies, 
indicating that these anti-VH antibodies did not react with non-Ig components. 
The reactivity of the anti-Vn antibodies with normal plasma cells was not restricted 
to any particular heavy chain class or light chain type  (Table V).  However, NF-11 
and SA-44 appeared to react with more #+ plasma cells than y+ and a + plasma cells, 
whereas MH-44 and GB-24 tended to react with higher proportions of the IgA plasma 
cells. 
When  viable lymphocytes obtained from  normal peripheral  blood were  stained 
with anti-VH antibodies, both surface Ig-bearing (sIg  +)  B cells and sIg- T  cells were 
shown to be unreactive (Table IV). The failure to stain sIg on viable B cells with anti- 
VH antibodies was consistent with the radioimmunoassay results (Fig. 2), indicating 
that the anti-VH antibodies did not bind intact Ig molecules. On the other hand, the 
anti-Vn antibodies were reactive with surface Ig molecules after air drying and acid- 
alcohol fixation of the cells. The frequencies of B cell subpopulations reactive with the 
four monoclonal anti-VH antibodies were very similar to those observed for plasma 
cells. By contrast, none of the anti-VH antibodies were reactive by immunofluorescence 
with T  cell constituents either before or after cell fixation and with or without PHA 
stimulation. 
The monoclonal anti-Vn antibodies were reactive with the intracytoplasmic  # chain 1018  ANTI-HUMAN  Vn  ANTIBODIES 
TABLE  III 
V~t Reactivity to Plasma Cells from Patients with Monoclonal Gammopathies, 
as Determined by Indirect Immunofluorescence* 
Patient 
Monoclonal  Plasma 
isotype  cells 
Percent VH  + cells among the indicated 
plasma cells 
MH-44  GB-24  NF- 11  SA-44 
HW  IgMx  #+  1  < 1  < 1  < 1 
007  IgMK  g+  < 1  95  100  95 
LK  IgM~¢  g+  96  < 1  <2  98 
SM  IgMX  /x  +  86  < 1  16  < 1 
GL  IgMX  #+  < 1  < 1  92  89 
010  IgDh  8  +  100  100  < 1  < 1 
MAH  IgG1.  7  +  1  < 1  < 1  < 1 
IS  IgGl~  y+  3  <1  1  <1 
WAT  IgGl,  y+  100  <1  99  <1 
VL  IgG~  y+  < 1  95  < l  < 1 
TAY  I gGl~  2/+  100  97  93  < 1 
JH  lgG2~  y+  <1  <1  <1  <l 
015  lgG4x  y+  100  97  < 1  < l 
001  lgAl~  a +  <1  <1  <1  <1 
003  IgA~,  o~  +  90  <2  5  <2 
WC  IgAl~  a +  99  1  97  < 1 
JN  IgAlx  c~  +  <1  <1  <1  <1 
AB  IgAlx  a +  <1  <1  <1  <1 
313  IgAl~,  ~+  <1  <1  <1  <1 
014  lgA2~  a +  <1  <1  <1  <1 
BRD  K  tc  +  1  <1  <1  <1 
OJ  K  K +  1  <1  1  <1 
IRW  K  K  +  <1  1  <1  <1 
DS  K  K  +  3  <1  <1  <1 
PR  ?t  ,k  +  <I  <l  <1  <1 
* Fixed bone marrow or blood plasma cells were stained for cytoplasmic Ig, as 
described in Materials and Methods. 
of pre-B  cells  in  bone  marrow  samples  from  fetuses  Table  IV).  The  frequencies  of 
VH + pre-B cells were three- to fivefold less than  those of VH  + plasma  cells, except  with 
the SA-44 antibody. 
These  results indicate  that  the monoclonal  anti-VH  antibodies  can  be used to detect 
heterogeneity  of  plasma  cells,  B  Cells,  and  pre-B  cells,  but  the  intact  surface  Ig 
molecules  on  viable  B  cells  are  not  recognized  by  these  antibodies  without  prior 
denaturation.  Vn  determinants  could  not  be  detected  at  all  by  immunofluorescence 
analysis of either resting or activated  T  cells. 
Discussion 
To  prepare  antibodies  against  common  VH  determinants  of human  Ig,  we  used 
hybridoma-derived  antibodies  rather  than  conventional  heteroandsera.  When  intact 
Ig  molecules  or  isolated  heavy  chains  were  used  as  immunogens,  we  did  not  obtain 
antibodies  that  were  reactive  with  V#  fragments  or  multiple  heavy  chain  isotypes. 
Monoclonal  anti-Vn  antibodies  could  be readily  obtained,  however,  by using  isolated 
Vg fragments  as immunogens.  Four  monoclonal  anti-VH  antibodies,  MH-44  (gt¢), GB- KUBAGAWA,  MAYUMI,  KEARNEY,  AND  COOPER  1019 
TABLE  IV 
Expression of Vtt Determinants by Normal Human Plasma Cells, Lymphocytes, and Pre-B Cells, as 
Determined by Indirect Immunofluorescence 
Cell phenotype and source 
Percent cells reactive with monoclonal anti-VH antibodies* 
MH-44  GB-24  NF- l 1  SA-44 
clg  ÷ plasma cells 
Bone marrow (N =  9):t:  34 +  11  14 +  5  I3 +  6  3 ±  2 
Spleen(N=6)  33+6  14+3  13+8  2+  1 
Tonsil (N =  4)  23 +  2  24 +- 8  ~3 -  5  4 +  3 
slg  + B cells 
Blood, viable (N =  5)  --<l.4  <0.l  <0.1  <0.1 
Blood,  fixed (N =  5)  38 -  7  13 ±  3  22 ±  9  6 +-- 1 
C#  + pre-B cells 
Fetal bone marrow§ (N =  6)  10 ±  7  3 __. 2  4 +  4  2 +  1 
T cells [[ 
Blood,  unstimulated (N =  5)  <0.02  <0.02  <0.02  <0.02 
Blood, PHA-stimulated (N =  3)  <0.05  <0.05  <0.05  <0.05 
* The results are recorded as the mean +  1 SD. 
:1: The number of specimens is given in parethesis. 
§ 14-17 wk of gestation. 
[[  T  cells  were  stained before  and  after acid-alchol fixation  in  an attempt  to detect  either surface or 
cytoplasmic VH determinants. 
TABLE  V 
Expression of VH Determinants by Each Class of Plasma Cells in Normal 
Bone Marrow Samples* 
Antibody 
Percent VH  + plasma cells among 
IgM  +  IgG  +  IgA  +  K  + 
MH-44  27 +  5  26 ±  4  36 +__ 8  35 +  6 
GB-24  15 +  2  15 +  7  22 +  8  18 +  10 
NF-11  18-1-9  8+5  7+2  14+  5 
SA-44  10+6  2+  1  5+  1  3+  l 
* The results indicate mean +  1 SD from five normal marrow samples. 
24  (ktx),  NF-11  ('/ax),  and  SA-44  (]tlX),  were  prepared  from  different  fusions.  The 
evidence  that  these  antibodies  are  directed  toward  VH,  rather  than  CH,  VL,  or  CL 
determinants,  is  as  follows:  (a)  they  react  with  their homologous  V/.t  fragments  and 
isolated/.t heavy  chains  but  not  with  the  intact  homologous  IgM  molecules  or  light 
chains,  (b)  they  also  react  with  pooled  normal  "/chains  but  not  with  the intact  IgG 
molecules  or  light  chains,  and  (c)  their  reactivities  are  not  restricted  to  particular 
heavy  chain  classes.  The  isolated  V/~  fragments  are  known  to  contain  about  15 
additional  amino-terminal  residues  of the C~1 domain  (24).  However,  the restriction 
of the reactivity of the anti-VH antibodies  to certain/1  chains and  the fact  that  they 
react  with  normal  ], chains and  isolated  heavy  chains of other  isotypes  rules out  the 
possibility that  these  antibodies  recognize  C/xa  determinants.  Moreover  VH  ÷  plasma 
cells in normal  bone  marrow  samples  were  found  among  all major  isotypes  ~,  y,  a, 
K) of plasma  cells, as determined  by immunofluorescence.  These data suggest that the 
four monoclonal  antibodies are indeed  directed toward  the VH determinant(s). 
All  four of the monoclonal  anti-VH  antibodies  reacted  with  isolated  heavy  chains 1020  ANTI-HUMAN VH ANTIBODIES 
but not with intact, undenatured Ig molecules, a finding anticipated from the ease of 
producing heavy and  light  chain-specific antibodies  directed  against  determinants 
that are not exposed on the intact molecule (36).  Procedures that might be expected 
to cause mild denaturation exposed the "hidden" VH determinants, e.g., adherence of 
the myeloma protein to a plastic surface was usually sufficient to allow reactivity with 
the  homologous  anti-VH  antibody  that  could  be  detected  by  an  enzyme-linked 
immunosorbent  assay  (data  not  shown).  Similarly, the  anti-VH  antibodies  did  not 
bind membrane-bound Ig molecules on viable B cells.  However, when blood mono- 
nuclear cells were pretreated with an acid-alcohol fixing solution, subpopulations of 
B cells were detectable by immunofluorescence staining with the monoclonal anti-Vn 
antibodies (37). The frequencies of the VH  + B cell subpopulations (38% MH-44  +, 13% 
GB-24  +, 22% NF- 11 +, 6% SA-44  +) were in close agreement with the relative frequencies 
of the  different  subpopulations  of VH  +  plasma  cell.  Indirect  immunofluorescence 
could  also  be  used  to  detect  subpopulations  of human  pre-B  cells  that  contain 
cytoplasmic/t heavy chains only. Thus, the anti-VH antibodies can be used to identify 
subpopulations  of B  lineage cells at  all stages  in  differentiation during which  they 
express heavy chains. 
The reactivity of the monoclonal anti-Vn antibodies with isolated heavy chains of 
known VH subgroups did not appear to correspond to the conventional VH subgroup 
typing.  The VH reaction spectra with  a  panel  of myeloma heavy chains and  with 
plasma  cells  from monoclonal gammopathy patients  revealed overlapping but  dis- 
tinctive patterns for the four antibodies  (Tables II and  III). 3-35% of normal bone 
marrow plasma cells were stained by immunofluorescence with the individual anti- 
VH  antibodies,  and,  when  combined,  they  stained  >50%  of normal  plasma  cells. 
Although human VH allotypes have been reported (38, 39), these anti-VH antibodies 
are apparently not allotype-specific for the following reasons:  (a)  plasma cells from 
over 20 individuals, including Caucasians,  Blacks, and Orientals, were stained with 
the anti-Vn antibodies in similar frequencies, and (b) the monoclonal anti-human VH 
antibodies were also reactive with Ig heavy chains of other mammals, including mouse 
(manuscript in preparation). These findings, thus, suggest that our anti-Vn antibodies 
recognize highly conserved but not subgroup-specific VH determinants and that each 
antibody recognizes a different VH epitope. 
Our  monoclonal anti-Vn  antibodies,  thus,  differ in specificity from the VH sub- 
group-specific  antibodies  reported  by  Natvig  and  his  colleagues  (3).  The  latter 
antibodies  were  raised  in  goats  or  rabbits  by  immunizing  with  intact  myeloma 
proteins with  known  VH and  VL subgroups.  Three sets  of antibodies  prepared  by 
selective adsorption  were  rendered specific for each  human VH  subgroup  without 
overlapping reaction, and these preparations reacted with intact Ig molecules as well 
as isolated heavy chains. We were unable to obtain monoclonal antibodies specific for 
the described human VH subgroups during the course of this study, suggesting that 
there might be a very limited number of unique determinants on human Ig that can 
elicit VH subgroup-specific antibodies in the mouse. It is possible that  a  mixture of 
different monoclonal anti-VH antibodies, each of which recognizes small populations 
of Ig molecules, might behave as VH subgroup-specific reagents analogous to the anti- 
VH subgroup antisera. 
Other investigators have also attempted to prepare heterologous antisera against 
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were raised in rabbits (16, 40-43, 45) or chickens (44) by immunizing with Fv (16) or 
Fab  (40)  fragments of mouse myeloma proteins and isolated heavy chains  (41), VH 
fragments (42, 44, 45), or intact molecules (43) of human myelomas. After appropriate 
absorptions, these antisera were rendered specific for idiotypic determinants (VH-VL), 
including cross-reactive idiotypes, and VH framework determinants, suggesting that 
these contain mixtures of antibodies with different specificities toward VH or VH plus 
VL. All of these antisera, with one exception (16), reacted with intact  Ig molecules 
better than with isolated heavy chains.  One antiserum, anti-Vn 315  (16), exhibited 
similar  reactivity to ours,  except for the  fact  that  it  also  contained  anti-idiotypic 
antibodies; our anti-VH antibodies did not recognize exposed determinants, even on 
the  homologous  myeloma  molecules.  Recently,  rabbit  antisera  against  similarly 
prepared mouse V# fragments have been characterized, and their reactivities appeared 
to be similar to our monoclonal anti-VH antibodies, except for their reactivity with 
intact Ig molecules,  z 
There is considerable evidence (46, 47) that T  cells and their products may express 
idiotypic or "framework" VH determinants, suggesting that Vn gene products in T 
cells may play an  important  role in  antigen recognition  (46,  47).  It  has also been 
reported that (a) the anti-VH 315 antibodies (16) inhibit T  cell function in mice (17- 
19)  and  cross-react  with  antigen-specific,  soluble  factors  of T  cells  (20,  21)  (b) 
unabsorbed chicken antisera against human V/~ fragments stain by immunofluores- 
cence ~30% of normal T  cells (44), and (c) unabsorbed rabbit antibodies against the 
VH fragments of a  human IgG3~ myeloma also show weak reactivity by immunoflu- 
orescence with ~20% of normal T  cells and may inhibit mixed lymphocyte reactions 
(45).  In contrast, our monoclonal anti-Vn antibodies appear unreactive by immuno- 
fluorescence  with  either  surface  or  cytoplasmic  components  of both  resting  and 
activated T  cells, and this is consistent with the results of others using goat anti-VH 
subgroup antibodies (48), rabbit anti-VH framework antibodies (42), and rabbit VH 
allotype  antibodies  (11-15).  Our  monoclonal  anti-Vn  subset  antibodies  could  be 
valuable reagents  in  the  future analysis  of this  issue  using very sensitive assays  of 
antigen-specific, soluble  factors of murine  and  human  T  cells.  They also  provide 
useful probes to analyze the expression of VH determinants produced by normal and 
abnormal B cells (37). 
Summary 
Hybridoma clones  secreting  antibodies  against  common  VH  determinants  were 
readily produced by fusion of cells from mice immunized with isolated V# fragments 
of human immunoglobulins  (Ig), but not with intact Ig molecules or isolated heavy 
chains. Four monoclonal antibodies to the Vg fragments of different IgM paraproteins 
were selected for analysis:  MH-44  (gl¢), GB-24  ~uK), NF-11  (3'1K), and  SA-44  (yll¢). 
Each antibody reacted with the homologous Vg fragment, homologous # chain, and 
normal 3' chains, but not with the intact IgM molecules, intact IgG, or isolated light 
chains, as determined by radioimmunoassay. The VH reaction spectra with a panel of 
myeloma  heavy  chains  showed  overlapping  but  distinctive  patterns  for  the  four 
antibodies. Each of the four monoclonal anti-VH antibodies appeared to react with a 
different "hidden" V~  determinant  that  is  not  exposed on undenatured,  intact  Ig 
Karjalainen, K. The preparation of mouse VH fragments and the characterization of heterologous 
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molecules and  differs from conventional VH subgroup determinants.  In immunoflu- 
orescence studies, the monoclonal anti-Vn antibodies did not  bind  to surface Ig on 
viable B lymphocytes, but visibly stained subpopulations of fixed B lymphocytes, pre- 
B cells, and normal plasma cells. The mean frequencies of VH + plasma cells were 30% 
(MH-44),  17%  (GB-24),  13%  (NF-11), and 3%  (SA-44), and similar frequencies were 
obtained for the VH + B cell subpopulations. While subpopulations of B cells could be 
identified  at  all  stages  in  differentiation  by  immunofluorescence  with  the  anti-Vn 
antibodies, neither resting nor activated T  cells expressed these VH determinants  in 
detectable amounts. 
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